Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biothera
ClinicalTrials.gov Identifier:
NCT01309126
First received: February 8, 2011
Last updated: December 8, 2015
Last verified: July 2015
  Purpose
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to treatment with either Imprime PGG and cetuximab or cetuximab alone. Subjects will be dosed until progression or discontinuation for some other reason. Efficacy will be assessed via Response Evaluation Criteria in Early Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans will be conducted every 6 weeks. Safety, pharmacokinetics (PK), quality of life, and biomarker parameters will also be assessed.

Condition Intervention Phase
Colorectal Cancer
Biological: Imprime PGG + cetuximab
Drug: Cetuximab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Biothera:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of complete response (CR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of partial response (PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of overall response (CR + PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    Samples for sparse PK will be taken at specified times on Cycle 1/Day 1 in the first 30 available subjects randomized to Arm 1 (Subjects 1-30). Samples will be collected, at multiple times, in the next 60 subjects randomized to Arm 1 who reach Cycle 2/Day 1 of dosing (subjects 31-90). Additionally, any subject after the first 90 subjects (subjects 91-795) who have a screening/baseline calculated creatinine clearance (based on age, weight and serum creatinine) of <60 mL/minute will have sparse PK samples collected.

  • Change in Quality of Life [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 795
Study Start Date: April 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Imprime PGG + cetuximab
Biological/Vaccine + Drug
Biological: Imprime PGG + cetuximab
Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
Other Names:
  • Imprime PGG
  • Cetuximab (Erbitux)
Active Comparator: Arm 2: cetuximab
Drug
Drug: Cetuximab
Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
Other Name: Cetuximab (Erbitux)

Detailed Description:

Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS WT colorectal cancer will be randomized in a 2:1 ratio to either:

Arm 1: Imprime PGG and cetuximab or Arm 2: Cetuximab

Approximately 795 subjects will be randomized into the study. Dosing will occur in 6-week cycles. Imprime PGG will be dosed at 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab (Arm 1 only). The initial cetuximab dose (both arms) will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2 administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36).

Subjects will be dosed until progressive disease (PD) per RECIST 1.1 or discontinuation of study drug for other reasons; e.g., safety. Following completion of the treatment period of the study, subjects will be monitored for survival until death or loss to follow-up. Tumor measurements and determination of tumor responses will be evaluated according to RECIST 1.1. Safety, PK, quality of life, and biomarker parameters will also be assessed.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Is >18 years old;
  2. Has recurrent or metastatic carcinoma of the colon or rectum with documented histological or cytological confirmation;
  3. Must be KRAS WT;
  4. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1;
  5. Has never received cetuximab or panitumumab, and has not received any treatment for colorectal cancer within 30 days prior to the first dose of study treatment under this protocol;
  6. Has an Eastern Cooperative Oncology Group (ECOG) score of 0-1, with a life expectancy of >3 months;
  7. Has received at least 2 prior chemotherapeutic regimens for colorectal cancer;
  8. Has adequate bone marrow reserve as evidenced by:

    • Absolute neutrophil count ≥1,500/μL
    • Platelets ≥100,000/μL;
  9. Has adequate renal function as evidenced by serum creatinine ≤2.5 × the upper limit of normal (ULN) for the reference lab;
  10. Has adequate hepatic function as evidenced by:

    • Aspartate aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects with known hepatic metastases)
    • Alanine aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects with known hepatic metastases)
    • Bilirubin <1.5 mg/dL or direct bilirubin <1.0 mg/dL
    • Serum Albumin >3.0 gm/dL
  11. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC); and
  12. If the subject is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 60 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method).

Exclusion Criteria:

  1. Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;
  2. Has a known hypersensitivity to baker's yeast or has an active yeast infection;
  3. Has had previous exposure to Betafectin® or Imprime PGG;
  4. Has an active, uncontrolled infection;
  5. Has known untreated or symptomatic brain metastases;
  6. Had a second malignancy within the previous 5 years, except for basal cell carcinoma, cervical intra-epithelial neoplasia or treated prostate cancer with a prostate-specific antigen (PSA) of <2.0 ng/mL;
  7. Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
  8. If female, is pregnant or breast-feeding;
  9. Is receiving concurrent standard and/or investigational anti-cancer therapy or has received such therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication); or
  10. Has previously received an organ or progenitor/stem cell transplant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01309126

  Hide Study Locations
Locations
United States, Alabama
Northwest Alabama Cancer Center
Florence, Alabama, United States, 35630
United States, Arkansas
Highlands Oncology Group
Bentonville, Arkansas, United States, 72703
United States, California
Pacific Medical Center
Anaheim, California, United States, 92801
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
Providence St. Joseph Medical Center
Burbank, California, United States, 91505
UCSD Moores Cancer Center
La Jolla, California, United States, 92903
Kenmar Research Institute
Los Angeles, California, United States, 90057
United States, Florida
AMPM Research Clinic
Miami Gardens, Florida, United States, 33169
MD Anderson Cancer Center
Orlando, Florida, United States, 32806
United States, Hawaii
University of Hawaii Cancer Center
Honolulu, Hawaii, United States, 96813
United States, Illinois
Medical and Surgical Specialists
Galesburg, Illinois, United States, 61401
Illinois Cancer Specialists
Niles, Illinois, United States, 60714
United States, Indiana
Indiana University Cancer Center
Beech Grove, Indiana, United States, 46237
United States, Kentucky
University of Louisville/James Brown Cancer Center
Louisville, Kentucky, United States, 40202
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Ellis Fischel Cancer Center at University of Missouri- Columbia
Columbia, Missouri, United States, 65203
United States, Nebraska
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
United States, New York
Hematology and Oncology Associates of Central NY
East Syracuse, New York, United States, 13057
New York Oncology, Hematology, P.C.
Hudson, New York, United States, 12534
United States, Ohio
Signal Point Hematology/Oncology
Middletown, Ohio, United States, 45042
Toledo Community Oncology Program- Toledo Community Hospital
Toledo, Ohio, United States, 43623
United States, Oregon
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States, 97401
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, South Carolina
Cancer Centers of the Carolinas
Spartanburg, South Carolina, United States, 29307
United States, Tennessee
The Jones Clinic
Germantown, Tennessee, United States, 38138
Tennessee Cancer Specialists
Knoxville, Tennessee, United States, 37915
United States, Texas
Texas Oncology-Amarillo
Amarillo, Texas, United States, 79106
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75201
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, United States, 75231
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States, 75246
Texas Oncology Denton South
Denton, Texas, United States, 76210
Texas Oncology - Fort Worth
Fort Worth, Texas, United States, 76104
Texas Oncology - Lewisville
Lewisville, Texas, United States, 75067
Texas Oncology-Seton Williamson
Round Rock, Texas, United States, 78665
Cancer Care Centers of South Texas
San Antonio, Texas, United States, 78217
Texas Oncology - Sherman
Sherman, Texas, United States, 75090
Texas Oncology - Tyler
Tyler, Texas, United States, 75702
United States, Utah
Northern Utah Associates
Ogden, Utah, United States, 84403
United States, Virginia
Virginia Oncology Associates
Newport News, Virginia, United States, 23606
Oncology and Hematology Associates of Southwest Virginia, Inc., dba Blue Ridge Cancer Care
Roanoke, Virginia, United States, 24014
France
Centre d' Oncologie de Gentilly
Nancy, France, 54000
Germany
Medizinisches Versorgungszentrum Ãrzteforum Seestrabe
Berlin, Germany, 13347
Ãrzteforum Henningsdorf Darmzentrum Oberhavel
Hennigsdorf, Germany, 16761
Klinikum Kassel GmbH Medizinische Klinik IV Onkologie, Hämatologie, Immunologie
Kassel, Hessen, Germany, 34125
Universitätsklinikum Köln - Studienzentrum der Klinik I für Innere Medizin
Koeln, Nordrhein Westfalen, Germany, 50937
Schwerpunktpraxis für Hämatologie und Onkologie
Magdeburg, Germany, 39104
Universitaetsklinikum Ulm
Ulm, Germany, 89081
Petruskrankenhaus Wuppertal, Klinik fuer Innere Medizin II- Gastroenterologie, Hepatologie und Diabetologie
Wuppertal, Germany, 42283
Puerto Rico
Fundacion de Investigacion de Diego
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
Biothera
  More Information

Additional Information:
Responsible Party: Biothera
ClinicalTrials.gov Identifier: NCT01309126     History of Changes
Other Study ID Numbers: BT-CL-PGG-CRC1031 
Study First Received: February 8, 2011
Last Updated: December 8, 2015
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
France: Ministry of Health

Keywords provided by Biothera:
Colorectal Cancer
KRAS Wild Type
Imprime PGG
Cetuximab
Phase 3
Efficacy
Safety
Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Cetuximab
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 25, 2016